These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31940430)

  • 1. Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry.
    Kollar A; Bütikofer L; Ochsenbein A; Stettler C; Trepp R
    Swiss Med Wkly; 2020 Jan; 150():w20176. PubMed ID: 31940430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage peptide receptor radionuclide therapy with [
    van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
    Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
    Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
    Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors.
    Riff BP; Yang YX; Soulen MC; Pryma DA; Bennett B; Wild D; Nicolas G; Teitelbaum UR; Metz DC
    Clin Nucl Med; 2015 Nov; 40(11):845-50. PubMed ID: 26284763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms.
    Borbath I; Garcia-Carbonero R; Bikmukhametov D; Jimenez-Fonseca P; Castaño A; Barkmanova J; Sedlackova E; Kollár A; Christ E; Kaltsas G; Kos-Kudla B; Maasberg S; Verslype C; Pape UF
    Eur J Cancer; 2022 Jun; 168():80-90. PubMed ID: 35472579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients.
    Hayes AR; Mak IYF; Evans N; Naik R; Crawford A; Khoo B; Grossman AB; Navalkissoor S; Watkins J; Luong TV; Mandair D; Toumpanakis C; Thirlwell C; Caplin ME; Meyer T
    Neuroendocrinology; 2021; 111(9):863-875. PubMed ID: 32950978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Scoville SD; Cloyd JM; Pawlik TM
    Expert Opin Pharmacother; 2020 Feb; 21(2):183-191. PubMed ID: 31760823
    [No Abstract]   [Full Text] [Related]  

  • 9. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies.
    Auernhammer CJ; Spitzweg C; Angele MK; Boeck S; Grossman A; Nölting S; Ilhan H; Knösel T; Mayerle J; Reincke M; Bartenstein P
    Lancet Diabetes Endocrinol; 2018 May; 6(5):404-415. PubMed ID: 29229497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on medical treatment of small intestinal neuroendocrine tumors.
    Pusceddu S; Femia D; Lo Russo G; Ortolani S; Milione M; Maccauro M; Vernieri C; Prinzi N; Concas L; Leuzzi L; De Braud F; Buzzoni R
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):969-76. PubMed ID: 27353232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and workup of 522 consecutive patients with neuroendocrine neoplasms in Switzerland.
    Gouffon M; Iff S; Ziegler K; Larche M; Schwarzenbach C; Prior JO; Matter M; Stettler C; Pralong FP
    Swiss Med Wkly; 2014 Feb; 144():w13924. PubMed ID: 24554450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
    Perez K; Chan J
    Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroendocrine Neoplasia within the German NET Registry].
    ; ;
    Z Gastroenterol; 2018 Oct; 56(10):1237-1246. PubMed ID: 30304748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Cloyd JM; Konda B; Shah MH; Pawlik TM
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Strosberg JR
    CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
    Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
    World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
    Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
    Rev Endocr Metab Disord; 2018 Jun; 19(2):145-158. PubMed ID: 29464446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.